SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics announces a $5.0M registered direct offering of…

Outlook Therapeutics, Inc. · PRESS-RELEASE filed May 28, 2026 at 16:00 ET

At the news

BEARISHIMPACT 7/10

PRESS-RELEASE filed May 28, 2026 at 16:00 ET

Outlook Therapeutics announces a $5.0M registered direct offering of 8.54M shares at $0.5855/share to its largest stockholder, GMS Ventures and Investments. The company also agrees to amend 15.49M outstanding warrants with a weighted average exercise price of $1.78 to a reduced exercise price of $0.5855, effective at closing. This dilutive capital raise comes as the company (market cap ~$71M) is commercializing LYTENAVA in Europe with an ongoing US FDA approval path. The aggressive warrant repricing creates massive potential dilution, effectively rewarding GMS with a near-$18M intrinsic-value transfer on existing warrants.

  • Registered direct offering of 8,539,709 shares at $0.5855/share for $5.0M gross proceeds
  • Offering priced at-the-market under Nasdaq rules to GMS Ventures and Investments (largest stockholder)
  • 15,488,570 outstanding warrants issued to GMS in Jan 2025 and May 2025 with weighted avg exercise price of $1.78 per share to be amended to $0.5855 per share at closing
  • Proceeds used for working capital and general corporate purposes

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access